UroStream

Prof. Tianxin Lin delivered an insightful presentation on the application of artificial intelligence in the precision diagnosis and treatment of bladder cancer. He highlighted the current diagnostic challenges related to…

Prof. Changwen Zhang presented a comprehensive update on the Chinese clinical exploration of ADC-based therapies in urothelial carcinoma. His presentation highlighted the promising role of Vedicitumab (RC48), a HER2-targeted ADC,…

?si=Je3YthZKHfx0xBY3

In his insightful presentation, Prof. Shan Liu shared an in-depth look into China's rapidly evolving surgical robot ecosystem, highlighting the comprehensive technical support and advanced maintenance services provided for robotic…

In this UroStream special from the 2025 EAU Congress, Professor Alicia K. Morgans from Dana-Farber Cancer Institute (USA) shares her expert insights into the evolving landscape of metastatic prostate cancer…

In recent years, the incidence of prostate cancer in China has continued to rise, creating an urgent need to improve diagnostic and treatment strategies tailored to this growing patient population. At the 5th Annual CUDA Yanqi Lake Meeting (2025), hosted by the Chinese Urological Doctor Association, UroStream invited Professor Liqun Zhou, Institute of Urology, Peking University, to discuss the importance of early screening, optimized diagnostic approaches, and advances in neoadjuvant therapy. His insights point toward practical steps for enhancing the survival and quality of life of prostate cancer patients in China.